The data reinforces acoramidis' competitive edge over tafamidis, likely supporting continued adoption. Monitor for potential guidance updates and upcoming label expansions. Stock could rally on the differentiated efficacy signals.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $64.68entry
- T+1 · 6mo ago +1.96%α +2.10% · $65.95
- T+5 · 6mo ago +0.99%α +1.07% · $65.32
- T+20 · 5mo ago +4.64%α +4.94% · $67.68
- T+60 · 3mo ago +26.76%α +22.37% · $81.99
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BridgeBio presented new acoramidis data at Heart Failure 2026, showing a 34% reduction in cardiovascular hospitalizations versus tafamidis (indirect comparison), early separation in outpatient worsening heart failure within 30 days (HR 0.59, p<0.0001), and sTTR variability reduction associated with lower all-cause mortality (HR 0.56, p=0.014). These results strengthen acoramidis' differentiation as a near-complete TTR stabilizer and could support further market share gains in ATTR-CM.
Key Facts
- Acoramidis reduced cardiovascular hospitalizations by 34% vs tafamidis (RRR 0.66, 95% CI 0.46–0.95) in a matching-adjusted indirect comparison.
- Acoramidis reduced the risk of outpatient worsening heart failure by 41% vs placebo (HR 0.59, p<0.0001), with separation seen within 30 days and sustained through Month 30.
- Lower sTTR variability and higher achieved sTTR levels were independently associated with reduced all-cause mortality (HR 0.56, p=0.014 and HR 0.46, p=0.014).
- Acoramidis blunted NT-proBNP increase by ~50% across all subgroups vs placebo.
- Acoramidis is approved as Attruby in the US and under other brand names in multiple ex-US markets.
Financial Impact
Positive for acoramidis commercial prospects; no direct financial figures provided.
Risk Factors
- Indirect comparison limitations and potential unmeasured confounders vs tafamidis.
- Future clinical or regulatory setbacks could reverse positive sentiment.
- Competition from other ATTR-CM therapies (e.g., Pfizer's tafamidis, gene silencers).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291995 |
Track record
38 reports on BBIO
9 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +25.55% at T+60 after the May 12, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers